Robert W. Baird Trims Immutep (NASDAQ:IMMP) Target Price to $6.00
Immutep (NASDAQ:IMMP – Free Report) had its price target trimmed by Robert W. Baird from $7.00 to $6.00 in a report issued on Thursday, Benzinga reports. The firm currently has an outperform rating on the biotechnology company’s stock. Separately, Capital One Financial initiated coverage on Immutep in a research note on Friday, May 17th. They […]
More Stories
Sparta Capital (CVE:SAY) Stock Price Down 25% – Time to Sell?
Shares of Sparta Capital Ltd. (CVE:SAY – Get Free Report) fell 25% during trading on Tuesday . The stock traded...
InterDigital (NASDAQ:IDCC) Shares Down 7.4% Following Insider Selling
InterDigital, Inc. (NASDAQ:IDCC – Get Free Report) dropped 7.4% during trading on Tuesday after an insider sold shares in the...
Kang Jyh Lee Sells 10,000 Shares of Photronics, Inc. (NASDAQ:PLAB) Stock
Photronics, Inc. (NASDAQ:PLAB – Get Free Report) CEO Kang Jyh Lee sold 10,000 shares of the stock in a transaction...
Northern Graphite (CVE:NGC) Trading 25% Higher – Here’s What Happened
Northern Graphite Co. (CVE:NGC – Get Free Report)’s stock price traded up 25% during mid-day trading on Tuesday . The...
One Wealth Capital Management LLC Takes $2.83 Million Position in Broadcom Inc. (NASDAQ:AVGO)
One Wealth Capital Management LLC acquired a new position in shares of Broadcom Inc. (NASDAQ:AVGO – Free Report) in the...
Cingulate Completes Final FDA Study for CTx-1301 ADHD Treatment
On January 7, 2025, Cingulate Inc. (NASDAQ:CING) announced the successful completion of its final FDA-required study for CTx-1301 (dexmethylphenidate) aimed...